Analisis Keuangan Saham 0K2H - Moleculin Biotech, Inc. (LSE) Stock

Gambaran Umum

Moleculin Biotech, Inc., based in the United States, operates within the biopharmaceutical industry and is primarily focused on the development of oncology drug candidates. Its portfolio includes projects targeting highly resistant tumors and viruses. Notable among its research endeavors is the development of Annamycin, which is being advanced as a potential treatment for acute myeloid leukemia. Additionally, Moleculin is exploring technologies designed to exploit the metabolism of tumors, including a focus on inhibitors that disrupt cancer cell glycolysis and the synthesis of glycosaminoglycans. These efforts embody the company's strategic intent to pioneer treatments for conditions with significant unmet medical needs, demonstrating a promising avenue in cancer treatment research and development.

Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih

Nilai operating income untuk Moleculin Biotech, Inc. per 2025 Jun 30 adalah -25.44 MM.
Nilai net income untuk Moleculin Biotech, Inc. per 2025 Jun 30 adalah -26.55 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30		-25.44	-26.55
2025-03-31		-25.91	-23.23
2024-12-31		-26.64	-21.76
2024-09-30		-28.92	-30.15
2024-06-30		-27.73	-25.17
2024-03-31		-27.95	-26.82
2023-12-31		-29.63	-29.77
2023-09-30		-27.76	-26.27
2023-06-30		-30.90	-29.27
2023-03-31		-31.92	-30.07
2022-12-31		-30.64	-29.02
2022-09-30		-28.80	-25.08
2022-06-30		-25.87	-20.85
2022-03-31		-23.95	-18.32
2021-12-31		-22.97	-15.89
2021-09-30		-21.26	-15.71
2021-06-30		-21.25	-14.72
2021-03-31		-20.77	-20.59
2020-12-31		-19.74	-17.36
2020-09-30		-21.06	-18.51
2020-06-30
2020-03-31

Laporan Laba Rugi: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31
2024-09-30	-11.22	-11.22
2024-06-30	-11.17	-11.17
2024-03-31	-12.69	-12.69
2023-12-31	-15.07
2023-09-30	-13.48	-13.48
2023-06-30	-15.18	-15.18
2023-03-31	-15.75	-15.75
2022-12-31	-15.22
2022-09-30	-13.16	-13.16
2022-06-30	-10.94	-10.94
2022-03-31	-9.62	-9.62
2021-12-31	-8.87
2021-09-30	-10.50	-10.50
2021-06-30	-12.36	-12.36
2021-03-31	-23.37	-23.37
2020-12-31	-26.44
2020-09-30	-30.75	-30.75
2020-06-30	-34.54	-34.54
2020-03-31	-20.32	-20.32

Arus Kas: Operasi, Investasi, Pendanaan

Nilai cash from operating activities untuk Moleculin Biotech, Inc. per 2025 Jun 30 adalah -21.34 MM.
Nilai cash from investing activities untuk Moleculin Biotech, Inc. per 2025 Jun 30 adalah 0.00 MM.
Nilai kas dari aktivitas pendanaan untuk Moleculin Biotech, Inc. per 2025 Jun 30 adalah 18.08 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-21.34	0.00	18.08
2025-03-31	-21.71	-0.01	12.63
2024-12-31	-23.86	-0.01	4.63
2024-09-30	-24.19	-0.09	9.10
2024-06-30	-25.11	-0.12	3.93
2024-03-31	-24.29	-0.12	4.00
2023-12-31	-23.59	-0.12	4.14
2023-09-30	-25.95	-0.04	0.19
2023-06-30	-25.98	-0.01	0.18
2023-03-31	-28.85	-0.06	0.12
2022-12-31	-27.64	-0.07	-0.02
2022-09-30	-24.64	-0.09	-0.02
2022-06-30	-21.35	-0.09	-0.04
2022-03-31	-20.13	-0.03	-0.02
2021-12-31	-18.95	-0.02	74.72
2021-09-30	-17.82	-0.01	80.21
2021-06-30	-18.90	-0.35	81.99
2021-03-31	-17.05	-0.37	92.01
2020-12-31	-17.77	-0.37	22.55
2020-09-30	-19.32	-0.37	17.07
2020-06-30
2020-03-31

Metrik Penilaian: PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Metrik Penilaian: EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Efektivitas Manajemen

roa untuk Moleculin Biotech, Inc. pada 2025 Jun 30 adalah -0.91.
roe untuk Moleculin Biotech, Inc. pada 2025 Jun 30 adalah -1.50.
roic untuk Moleculin Biotech, Inc. pada 2025 Jun 30 adalah -47.21.
croic untuk Moleculin Biotech, Inc. pada 2025 Jun 30 adalah -18.51.
ocroic untuk Moleculin Biotech, Inc. pada 2025 Jun 30 adalah -44.12.

Period End (TTM)	ROA	ROE	ROIC (Tingkat Pengembalian Investasi Modal)	CROIC	OCROIC
2025-06-30	-0.91	-1.50	-47.21	-18.51	-44.12
2025-03-31	-0.71	-1.01	-3.37	-2.98	-3.70
2024-12-31	-0.79	-0.83	-3.78	-1.90	-3.03
2024-09-30	-0.64	-0.86	-1.38	-1.17	-1.41
2024-06-30	-0.53	-0.59	-1.21	-0.92	-1.12
2024-03-31	-0.52	-0.57	-1.12	-0.74	-0.90
2023-12-31	-0.40	-0.45	-0.74	-0.72	-0.73
2023-09-30	-0.40	-0.44	-0.72	-0.64	-0.64
2023-06-30	-0.41	-0.44	-0.72	-0.63	-0.64
2023-03-31	-0.37	-0.40	-0.65	-0.63	-0.63
2022-12-31	-0.28	-0.31	-0.43	-0.42	-0.42
2022-09-30	-0.24	-0.31	-0.43	-0.42	-0.42
2022-06-30	-0.20	-0.25	-0.31	-0.32	-0.32
2022-03-31	-0.16	-0.21	-0.25	-0.28	-0.28
2021-12-31	-0.54	-0.89	-0.20	0.70	-0.22
2021-09-30	-0.58	-1.09	-0.19	0.77	-0.22
2021-06-30	-0.47	-0.94	-0.17	0.74	-0.22
2021-03-31	-0.81	-1.35	-0.23	0.84	-0.19
2020-12-31	-0.69	-1.11	-0.96	0.25	-0.99
2020-09-30	-0.61	-0.98	-1.25	-0.18	-1.31
2020-06-30	-0.60	-0.87	-1.21	-0.12	-1.08
2020-03-31	-0.49	-0.71	-0.66	0.18	-1.13

Gross Margins

Margin Kotor: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Margin Keuntungan Bersih: Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.

Margin Operasi: Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.

Period End (TTM)	Margin Kotor	Margin Keuntungan Bersih	Margin Operasi
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31